Director/PDMR Shareholding

RNS Number : 8160U

MaxCyte, Inc.

30 March 2023

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

PDMR Dealing

Gaithersburg, Maryland - 30 March 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 29 March 2023 Richard Douglas, Non-Executive Chairman of the Company, purchased 80,000 shares on the open market of common stock in the Company ("Common Stock"). The 80,000 shares of Common Stock were purchased at an average price of $4.3185 per Common stock.

Following the purchase of Common Stock, Richard Douglas holds a total of 100,000 Common Stock representing approximately 0.1 percent of the issued share capital of the Company. Richard Douglas holds a further 158,500 options over Common Stock.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™,GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn .

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Richard Douglas
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Purchase of common stock
c)	Price(s) and volume(s)
			Purchase Price(s) range	Volume(s)
			$4.20-$4.35	80,000
d)	Aggregated information
	- Aggregated volume	80,000
	- Price	$4.3185
e)	Date of the transaction	29 March 2023
f)	Place of the transaction	USStock Exchange, Nasdaq

 

END

 

 

DSHEAFDEDLDDEFA